USA - NASDAQ:BIAF - US09076W1099 - Common Stock
The current stock price of BIAF is 3.41 USD. In the past month the price decreased by -32.78%. In the past year, price decreased by -91.94%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.42 | 400.78B | ||
AMGN | AMGEN INC | 13.56 | 159.25B | ||
GILD | GILEAD SCIENCES INC | 15.23 | 146.23B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 24.12 | 104.76B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.06B | ||
REGN | REGENERON PHARMACEUTICALS | 12.47 | 60.33B | ||
ARGX | ARGENX SE - ADR | 90.32 | 51.24B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.14 | 34.93B | ||
INSM | INSMED INC | N/A | 34.49B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.26B | ||
NTRA | NATERA INC | N/A | 24.78B | ||
BIIB | BIOGEN INC | 8.89 | 20.86B |
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas and currently employs 57 full-time employees. The company went IPO on 2022-08-26. The company develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
BIOAFFINITY TECHNOLOGIES INC
3300 Nacogdoches Road, Suite 216
San Antonio TEXAS US
Employees: 57
Phone: 12106985334
The current stock price of BIAF is 3.41 USD. The price increased by 25.83% in the last trading session.
The exchange symbol of BIOAFFINITY TECHNOLOGIES INC is BIAF and it is listed on the Nasdaq exchange.
BIAF stock is listed on the Nasdaq exchange.
BIOAFFINITY TECHNOLOGIES INC (BIAF) has a market capitalization of 3.38M USD. This makes BIAF a Nano Cap stock.
BIOAFFINITY TECHNOLOGIES INC (BIAF) currently has 57 employees.
BIOAFFINITY TECHNOLOGIES INC (BIAF) has a support level at 3.4 and a resistance level at 6.04. Check the full technical report for a detailed analysis of BIAF support and resistance levels.
The Revenue of BIOAFFINITY TECHNOLOGIES INC (BIAF) is expected to decline by -36.4% in the next year. Check the estimates tab for more information on the BIAF EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BIAF does not pay a dividend.
BIOAFFINITY TECHNOLOGIES INC (BIAF) will report earnings on 2025-11-12.
BIOAFFINITY TECHNOLOGIES INC (BIAF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.27).
ChartMill assigns a fundamental rating of 1 / 10 to BIAF. Both the profitability and financial health of BIAF have multiple concerns.
Over the last trailing twelve months BIAF reported a non-GAAP Earnings per Share(EPS) of -10.27. The EPS increased by 22.81% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -246.03% | ||
ROE | N/A | ||
Debt/Equity | N/A |
For the next year, analysts expect an EPS growth of 41.46% and a revenue growth -36.4% for BIAF